Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Apellis Pharmaceuticals Inc Stock Research

APLS

49.69USD+1.39(+2.88%)Delayedas of 20 Sep 2023, 12:32 pm
Watchlist

Market Summary

USD49.69+1.39
Delayedas of 20 Sep 2023, 12:32 pm
2.88%

APLS Alerts

  • 2 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Losses in recent quarter

APLS Stock Price

APLS RSI Chart

APLS Valuation

Market Cap

5.7B

Price/Earnings (Trailing)

-8.64

Price/Sales (Trailing)

30.78

EV/EBITDA

-7.76

Price/Free Cashflow

-9.09

APLS Price/Sales (Trailing)

APLS Profitability

EBT Margin

-652.84%

Return on Equity

-167.67%

Return on Assets

-70.59%

Free Cashflow Yield

-11%

APLS Fundamentals

APLS Revenue

Revenue (TTM)

184.5M

Revenue Y/Y

481.85%

Revenue Q/Q

111.77%

APLS Earnings

Earnings (TTM)

-657.1M

Earnings Y/Y

21.76%

Earnings Q/Q

31.35%

Price Action

52 Week Range

19.8394.75
(Low)(High)

Last 7 days

14.4%

Last 30 days

57.6%

Last 90 days

-44.8%

Trailing 12 Months

-24.3%

APLS Financial Health

Current Ratio

6.88

APLS Investor Care

Shares Dilution (1Y)

10.05%

Diluted EPS (TTM)

-5.83

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for APLS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-15
Machiels Alec
sold
-56,675
45.34
-1,250
-
2023-09-15
Machiels Alec
acquired
3,337
2.67
1,250
-
2023-09-14
Chopas James George
acquired
-
-
2,500
vp/chief accounting officer
2023-09-08
Deschatelets Pascal
acquired
49,395
2.67
18,500
chief scientific officer
2023-09-08
Deschatelets Pascal
sold
-514,440
42.87
-12,000
chief scientific officer
2023-09-06
SCHEIBLER LUKAS
sold
-75,525
43.01
-1,756
chief research officer
2023-09-01
Francois Cedric
sold
-6,262,960
41.7531
-150,000
chief executive officer
2023-09-01
Francois Cedric
acquired
801,000
2.67
300,000
chief executive officer
2023-08-31
Chopas James George
sold
-22,715
41.226
-551
vp/chief accounting officer
2023-08-08
Deschatelets Pascal
acquired
49,395
2.67
18,500
chief scientific officer

1–10 of 50

Which funds bought or sold APLS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-12
Farther Finance Advisors, LLC
unchanged
-
327
1,184
-%
2023-08-24
Alberta Investment Management Corp
sold off
-100
-264,829
-
-%
2023-08-24
PERCEPTIVE ADVISORS LLC
added
46.22
37,346,100
73,976,600
2.14%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
reduced
-37.04
-92,888
619,480
0.01%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-65.1
-486,438
452,409
-%
2023-08-21
Affinity Asset Advisors, LLC
reduced
-71.43
-1,397,600
911,000
0.32%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
reduced
-57.25
-1,479,000
2,131,000
0.02%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-7.21
2,091,470
9,518,770
0.01%
2023-08-18
Legato Capital Management LLC
added
27.31
348,180
807,328
0.11%
2023-08-17
Orion Portfolio Solutions, LLC
reduced
-3.71
377,064
1,519,820
0.02%

1–10 of 35

Latest Funds Activity

Are funds buying APLS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own APLS
No. of Funds

Schedule 13G FIlings of Apellis Pharmaceuticals

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Sep 08, 2023
wellington management group llp
12.55%
14,770,859
SC 13G/A
Jul 18, 2023
ecor1 capital, llc
5.4%
6,307,547
SC 13G
Jul 07, 2023
blackrock inc.
4.9%
5,747,184
SC 13G/A
Feb 14, 2023
t. rowe price investment management, inc.
5.3%
5,842,660
SC 13G
Feb 14, 2023
avoro capital advisors llc
9.6%
10,625,000
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
2.5%
2,749,542
SC 13G/A
Feb 09, 2023
vanguard group inc
8.33%
9,212,491
SC 13G/A
Feb 06, 2023
wellington management group llp
7.98%
8,820,398
SC 13G/A
Feb 01, 2023
blackrock inc.
7.0%
7,704,194
SC 13G/A
Feb 14, 2022
morningside venture investments ltd
13.2%
12,806,342
SC 13G/A

Recent SEC filings of Apellis Pharmaceuticals

View All Filings
Date Filed Form Type Document
Sep 19, 2023
4
Insider Trading
Sep 19, 2023
4
Insider Trading
Sep 18, 2023
144
Notice of Insider Sale Intent
Sep 18, 2023
144
Notice of Insider Sale Intent
Sep 18, 2023
4
Insider Trading
Sep 18, 2023
4
Insider Trading
Sep 15, 2023
144
Notice of Insider Sale Intent
Sep 11, 2023
4
Insider Trading
Sep 08, 2023
144
Notice of Insider Sale Intent
Sep 08, 2023
SC 13G/A
Major Ownership Report

Peers (Alternatives to Apellis Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
287.4B
1.8B
8.19% 34.91%
-165.92
158.74
69.45% 14.65%
271.2B
56.0B
2.23% 8.69%
31.23
4.84
-2.31% -31.27%
92.4B
9.5B
3.90% 25.64%
27.45
9.72
13.83% 5.33%
89.5B
12.7B
3.00% 16.97%
20.83
7.07
-10.94% -24.40%
21.9B
1.2B
-5.57% -18.68%
-20.63
17.73
39.94% -8.44%
11.1B
1.0B
6.45% 3.35%
-12.24
11.07
20.15% -79.16%
10.4B
2.1B
-3.97% 1.74%
11.88
4.9
18.01% 38.16%
MID-CAP
3.1B
-
-5.78% 157.92%
-9.48
-
- -28.88%
3.1B
225.6M
4.14% -26.79%
-5.62
13.8
-2.11% 21.02%
2.6B
402.9M
3.70% -20.53%
-3.61
6.46
20.50% -42.46%
1.9B
27.2M
-16.17% -58.23%
-2.56
69.33
- -14.43%
SMALL-CAP
3.1B
-
1.51% -37.05%
-7.31
33.28
34.30% -149.91%
1.4B
302.9M
-11.98% -2.00%
11.71
4.47
77.72% 112.02%
283.7M
152.5M
-7.29% 31.99%
38.08
1.86
127.84% 103.41%
30.6M
-
-1.14% 3544.51%
-0.66
-
- -31.51%

Apellis Pharmaceuticals News

Digital Journal
APLS INVESTOR NOTICE: Apellis Pharmaceuticals, Inc. Investors ....
Digital Journal,
44 minutes ago
GuruFocus.com
Yahoo Entertainment
GlobeNewswire
Proactive Investors USA
Proactive Investors USA

Returns for APLS

Cumulative Returns on APLS

19.3%


5-Year Cumulative Returns

14.0%


3-Year Cumulative Returns

Risks for APLS

What is the probability of a big loss on APLS?

100%


Probability that Apellis Pharmaceuticals stock will be more than 20% underwater in next one year

74.6%


Probability that Apellis Pharmaceuticals stock will be more than 30% underwater in next one year.

55.4%


Probability that Apellis Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does APLS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Apellis Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Financials for Apellis Pharmaceuticals

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue74.3%184,534,000105,887,00075,422,000113,049,00096,643,00080,944,00066,563,000112,583,750158,604,500204,625,250250,646,000128,383,3906,120,7796,516,7795,108,7795,121,8144,638,2394,004,9042,960,7712,728,6552,376,132
Operating Expenses6.8%797,049,000746,585,000670,035,000633,013,000591,664,000621,628,000602,840,000573,025,000569,578,000490,176,000464,372,000468,861,333388,528,000-288,015,000279,792,000--127,925,000--
  S&GA Expenses14.7%376,240,000328,070,000277,163,000234,258,000201,615,000187,379,000176,771,000179,801,000171,029,000150,476,000139,401,000122,377,000104,015,00088,379,00067,046,00045,968,79733,604,92226,774,74522,639,00021,108,16416,914,476
  R&D Expenses-1.5%400,315,000406,318,000387,236,000365,994,000358,520,000352,802,000345,869,000318,025,000323,499,000314,650,000299,921,000328,055,000286,167,000249,771,000220,969,000173,303,035151,523,491128,363,110105,286,00087,612,81867,591,244
EBITDA100.0%--686,390,000-644,948,000-625,082,000-628,220,000-705,630,000-734,358,000-794,162,000-788,526,000-327,036,000-330,100,000-291,749,994-300,619,473-300,479,000-303,720,000------
EBITDA Margin100.0%--6.48-8.55-5.53-6.50-8.65-11.03-7.05-4.97-1.60-1.32-2.27-49.12-46.11-59.45------
Interest Expenses0%3,286,0003,286,0005,003,0005,003,0006,732,0006,732,00010,265,00010,265,00015,993,00015,993,00012,929,00012,957,0004,088,0004,228,000987,0001,436,3061,535,7221,852,2501,816,0001,338,6941,344,371
Earnings Before Taxes4.9%-657,624,000-691,272,000-651,503,000-631,622,000-636,370,000-700,070,000-746,002,000-797,894,666-805,700,000-734,636,000-343,029,000----304,707,000----127,502,000--
EBT Margin100.0%--6.53-8.64-5.59-6.58-8.75-11.21-7.16-5.08-1.68-1.37-2.37-49.79-46.76-59.64------
Net Income4.9%-657,075,000-691,015,000-652,172,000-634,114,000-638,416,000-701,630,000-746,354,000-520,156,000-460,285,000-359,711,000-344,874,000-536,357,000-470,482,000-422,955,000-304,707,000-227,948,475-194,095,590-156,339,890-127,502,194-109,298,615-84,899,773
Net Income Margin100.0%--6.53-8.65-5.61-6.61-8.60-11.21-4.62-2.90-1.76-1.38-4.18-76.87-64.90-59.64------
Free Cashflow100.0%--581,502,000-515,269,000-486,192,000-500,556,000-522,077,000-564,229,000-310,443,000-245,028,000-210,924,000-165,910,000-389,404,238-339,910,389-285,176,516-212,828,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-6.5%9169797608731,0021,146882526700810961768870689389466317318204239267
  Current Assets-6.5%8939547208329601,104824475655774917742854672373451308311202239267
    Cash Equivalents-19.5%616765552584604633642284271265566416317418352434289288176221254
  Inventory20.7%10385.0086.0060.0048.0033.0016.002.004.00------------
  Net PPE-10.5%5.006.006.006.006.006.006.007.007.007.007.007.002.002.002.002.001.001.001.00--
Liabilities0.6%57056759056566868468358384175875666263843035532715894.0043.0043.0037.00
  Current Liabilities26.1%17513916811512712513294.0015884.0012875.0058.0051.0066.0045.0036.0020.0017.0016.0010.00
Shareholder's Equity-16.2%345412170307334462199--52.0020510623225934.00140159225161196230
  Retained Earnings-4.9%-2,608-2,486-2,308-2,142-1,951-1,795-1,656-1,508-1,313-1,093-926-1,004-868-750-581-468-398-327-276-240-204
  Additional Paid-In Capital1.9%2,9552,9002,4802,4532,2892,2601,8571,4531,1741,1471,1311,1121,1011,008616608558552438436434
Shares Outstanding1.2%11811611111010710698.0087.0081.0079.0076.0075.0075.0074.0062.0064.0064.0063.0054.0054.0055.00
Cashflow (Last 12 Months)
Cashflow (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-7.4%-622,936,000-579,805,000-513,745,000-485,500,000-499,708,000-521,372,000-563,126,000-308,648,000-239,847,000-205,453,000-160,488,000-384,538,000-338,311,000-283,924,000-211,135,000-173,542,426-153,077,874-143,865,751-131,241,000-102,295,378-80,300,798
  Share Based Compensation6.8%105,883,00099,135,00091,085,00086,156,00079,809,00075,001,00070,667,00063,849,00058,754,00052,521,00045,376,00039,989,00033,185,00025,879,00021,144,00015,865,36112,621,28510,681,8127,733,00010,068,9798,563,592
Cashflow From Investing-25.1%248,282,000331,583,00059,893,00020,744,00075,609,000122,432,000247,616,000162,545,000181,659,000-235,900,000-316,989,000-317,053,000-516,287,000-228,672,000-1,693,000-2,050,666-2,134,000-3,500,000---
Cashflow From Financing1.7%386,356,000380,061,000365,659,000765,563,000758,047,000767,308,000392,236,00014,595,00013,401,000290,543,000692,178,000686,070,000884,094,000643,390,000388,541,000388,447,297189,458,863280,098,303131,903,000309,828,188413,155,496

APLS Income Statement

2023-06-30
Condensed Consolidated Statements of Operations and Comprehensive Income/(Loss) (Unaudited) - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:    
Revenue$ 94,969$ 16,322$ 139,814$ 30,703
Operating expenses:    
Cost of sales8,3798216,1881,329
Research and development95,658101,661205,684192,606
General and administrative111,37363,203213,466114,390
Total operating expenses:215,410164,946435,338308,325
Net operating loss(120,441)(148,624)(295,524)(277,622)
Interest income6,0021,43211,3951,530
Interest expense(7,341)(8,448)(14,869)(16,986)
Other (expense)/income, net(63)149(341)(140)
Net loss before taxes(121,843)(155,491)(299,339)(293,218)
Income tax expense1944864761,694
Net loss(122,037)(155,977)(299,815)(294,912)
Other comprehensive gain/(loss):    
Unrealized gain/(loss) on marketable securities (766) (818)
Foreign currency gain(21)(369)79(286)
Total other comprehensive income/(loss)(21)(1,135)79(1,104)
Comprehensive loss, net of tax$ (122,058)$ (157,112)$ (299,736)$ (296,016)
Net loss per common share, basic$ (1.02)$ (1.46)$ (2.57)$ (2.88)
Net loss per common share, diluted$ (1.02)$ (1.46)$ (2.57)$ (2.88)
Weighted-average number of common shares used in net loss per common share, basic119,316106,630116,594102,349
Weighted-average number of common shares used in net loss per common share, diluted119,316106,630116,594102,349
Product Revenue, Net [Member]    
Revenue:    
Revenue$ 89,645$ 15,654$ 128,444$ 27,763
Licensing and other revenue [Member]    
Revenue:    
Revenue$ 5,324$ 668$ 11,370$ 2,940

APLS Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 616,259$ 551,801
Accounts receivable110,9137,727
Inventory103,21685,714
Prepaid assets34,40436,350
Restricted cash1,0851,273
Other current assets26,80936,658
Total current assets892,686719,523
Non-current assets:  
Right-of-use assets16,72618,747
Property and equipment, net5,3396,148
Other assets82715,799
Total assets915,578760,217
Current liabilities:  
Accounts payable27,50037,342
Accrued expenses97,71695,139
Current portion of development liability43,76929,504
Current portion of right-of-use liabilities5,8525,625
Total current liabilities174,837167,610
Long-term liabilities:  
Long-term development liability289,960315,647
Convertible senior notes92,88392,736
Right-of-use liabilities12,06614,352
Other liabilities429 
Total liabilities570,175590,345
Stockholders' equity:  
Preferred stock, $0.0001 par value; 10,000 shares authorized, and zero shares issued and outstanding at June 30, 2023 and December 31, 202200
Common stock, $0.0001 par value; 200,000 shares authorized at June 30, 2023 and December 31, 2022; 117,579 shares issued and outstanding at June 30, 2023, and 110,772 shares issued and outstanding at December 31, 20221211
Additional paid-in capital2,954,8622,479,596
Accumulated other comprehensive loss(796)(875)
Accumulated deficit(2,608,675)(2,308,860)
Total stockholders' equity345,403169,872
Total liabilities and stockholders' equity$ 915,578$ 760,217
Cedric Francois
480
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.